In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Rocket Pharmaceuticals Inc (NASDAQ: RCKT) closed at $18.95 in the last session, down -0.47% from day before closing price of $19.04. In other words, the price has decreased by -$0.47 from its previous closing price. On the day, 0.57 million shares were traded. RCKT stock price reached its highest trading level at $19.1594 during the session, while it also had its lowest trading level at $18.46.
Ratios:
We take a closer look at RCKT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.79 and its Current Ratio is at 7.79. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on April 02, 2024, initiated with a Neutral rating and assigned the stock a target price of $39.
On October 24, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $65.
On February 01, 2023, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $45.Morgan Stanley initiated its Overweight rating on February 01, 2023, with a $45 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 22 ’24 when Militello John sold 812 shares for $23.02 per share. The transaction valued at 18,688 led to the insider holds 52,515 shares of the business.
White Mark Andrew sold 3,026 shares of RCKT for $61,715 on Jul 08 ’24. The insider now owns 72,220 shares after completing the transaction at $20.39 per share. On May 16 ’24, another insider, Shah Gaurav, who serves as the CEO of the company, sold 9,790 shares for $23.35 each. As a result, the insider received 228,596 and left with 728,069 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCKT now has a Market Capitalization of 1723993472 and an Enterprise Value of 1470965504.
Stock Price History:
Over the past 52 weeks, RCKT has reached a high of $32.53, while it has fallen to a 52-week low of $14.89. The 50-Day Moving Average of the stock is -14.49%, while the 200-Day Moving Average is calculated to be -23.03%.
Shares Statistics:
According to the various share statistics, RCKT traded on average about 821.00K shares per day over the past 3-months and 834340 shares per day over the past 10 days. A total of 90.28M shares are outstanding, with a floating share count of 83.87M. Insiders hold about 7.81% of the company’s shares, while institutions hold 99.24% stake in the company. Shares short for RCKT as of 1721001600 were 9642489 with a Short Ratio of 12.83, compared to 1718323200 on 9262160. Therefore, it implies a Short% of Shares Outstanding of 9642489 and a Short% of Float of 22.600001.
Earnings Estimates
The current rating of Rocket Pharmaceuticals Inc (RCKT) reflects the combined expertise of 14.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.69, with high estimates of $0.24 and low estimates of -$0.9.
Analysts are recommending an EPS of between -$1.59 and -$3.1 for the fiscal current year, implying an average EPS of -$2.81. EPS for the following year is -$2.56, with 14.0 analysts recommending between -$1.51 and -$3.21.
Revenue Estimates
Based on 10 analysts’ estimates, the company’s revenue will be $67.18M in the next fiscal year. The high estimate is $117.96M and the low estimate is $5M.
